ATAGI have provided recommendations for the use of the Pfizer bivalent COVID vaccine following its recent provisional approval by the TGA. This means that there are now 2 bivalent COVID vaccines available for use within Australia- Moderna and Pfizer. 

The Pfizer bivalent vaccine contains equal parts of mRNA from the spike protein of the original SARS-CoV-2 virus and the Omicron BA.1 variant.  

ATAGI recommends that the Pfizer bivalent vaccine may be given to anyone aged 18 years or over who is eligible for a booster dose. It is not recommended for use in a primary course of COVID vaccination.  

There is no preference for either brand of bivalent or original mRNA COVID vaccines as a booster dose. 

For read the ATAGI recommendations in full, head to the link below: 

ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine

MVEC acknowledges the traditional owners of the lands on which we live, work and educate. We pay our respects to their Elders, past, present and emerging.
We are committed to honouring Australian Aboriginal and Torres Strait Islander peoples’ unique cultural and spiritual relationships to the land, waters and seas.

About MVEC

The Melbourne Vaccine Education Centre (MVEC) is an educational website, developed with the aim of providing up-to-date immunisation information for both healthcare professionals and members of the public. We are based at Murdoch Children’s Research Institute (MCRI), a research organisation, and are affiliated with SAEFVIC (Surveillance of Adverse Events Following Vaccination in the Community), the Victorian Vaccine Safety Service.

Share This